Positive Results from Phase Three Study of Tarceva: A New Approach to Treating Solid Tumors

Tarceva is a promising new oral anti-cancer drug belonging to a new class of drugs called epidermal growth factor receptor inhibitors. It has shown positive results in phase three studies for non-small cell lung cancer and pancreatic cancer. By inhibiting the activity of EGFR, a protein found on tumor cells, Tarceva effectively slows down tumor growth and improves overall survival rates. With minimal side effects compared to chemotherapy, this drug offers hope for patients with difficult-to-treat cancers.